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Abstract
Background: Nosocomial Infections (NI) are a frequent and relevant problem. The purpose of this study was to
determine the epidemiology of the three most common NI in a Pediatric Intensive Care Unit from a developing
country.
Methods: We performed a prospective study in a single Pediatric Intensive Care Unit during 12 months. Children
were assessed for 3 NI: bloodstream infections (BSI), ventilator-associated pneumonia (VAP) and urinary tract
infections (UTI), according to Center for Disease Control criteria. Use of devices (endotracheal tube [ETT], central
venous catheter [CVC] and urinary catheter [UC]) was recorded.
Results: Four hundred fourteen patients were admitted; 81 patients (19.5%) developed 85 NIs. Density of incidence
of BSI, VAP and UTI was 18.1, 7.9 and 5.1/1000 days of use of CVC, ETT and UC respectively. BSI was more common
in children with CVCs than in those without CVCs (20% vs. 4.7%, p < 0.05). Candida spp. was the commonest
microorganism in BSI (41%), followed by Coagulase-negative Staphylococcus (17%). Pseudomonas (52%) was the
most common germ for VAP and Candida (71%) for UTI. The presence of NI was associated with increased
mortality (38.2% vs. 20.4% in children without NI; p < 0.001) and the median length of ICU stay (23 vs. 6 days in
children without NI; p < 0.001). Children with NI had longer average hospital stay previous to diagnosis of this
condition (12.3 vs. 6 days; p < 0.001).
Conclusions: One of every 5 children acquires an NI in the PICU. Its presence was associated with increased
mortality and length of stay. At the same time a longer stay was associated with an increased risk of
developing NI.
Background
Nosocomial Infections (NIs) are a frequent problem,
particularly in Intensive Care Units (ICU). In Europe,
incidences range from 1% in General Pediatric wards up
to 23.6% in Pediatric ICUs (PICU) [1]. PICU studies
report incidences between 6.1 - 15.1% [2,3] whilst a
cross-sectional study found a prevalence of 11.9% [4].
Bloodstream infections (BSI) are the most common NI
in PICUs (28-52% of all) [2-6]; pneumonia (including
ventilator associated pneumonia, VAP) and urinary tract
infection (UTI), followed by enteric, surgical site and skin
[1-4]. BSI and pneumonia are responsible for
approximately 50% of NIs, and UTI causes an additional
12-22% [3,7]. Although VAP is the most frequent NI in
adults (8 - 28% of adults under mechanical ventilation,
MV, developed VAP [8]), pediatric studies report inci-
dences of 2 - 17% [9-12]. Only two pediatric studies have
found VAP to be the most frequent NI in PICU [1,13].
All aforementioned studies, except two [12,13], come
from developed countries. In contrast to PICUs from
developed countries, those in developing countries often
admit more critically ill patients, with medical conditions
rather than surgical, and with lower ages and socioeco-
nomic level [14]. A study from Brazil found that yeasts
and Gram negative bacteria were the most frequent iso-
lates in blood cultures [13]. Another study in adults from
developing countries found greater frequency of NI com-
pared to ICUs in the USA, despite similar device use
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any medium, provided the original work is properly cited.rates [15]. So, it is possible that there could be differences
in the demographic and epidemiologic characteristics of
NI in PICUs from developing countries. The objective of
this study was to understand the epidemiological profile
of the 3 most common NIs (BSI, VAP and UTI) in a
PICU of a developing country.
Methods
A prospective study, which followed rules of active epi-
demiologic surveillance, was performed in the PICU at
the Instituto Nacional de Salud del Niño (INSN) of
Lima, Peru. This is a national reference center admitting
patients from all over the country. It has 16 beds for
children between 0 and 18 years, admitting around 500
patients per year. Cardiac surgery and burn patients
have a dedicated ICU. Usually no preterm infants are
admitted to the PICU, and no prophylactic antibiotic or
antifungal therapy is given for high risk newborns. Most
admissions come from the Emergency Department.
This study, approved by the Committees on Ethics of
the INSN and the Instituto Nacional de Salud (INS) of
Lima occurred over a twelve month period (June 21st
2006 through to June 20th 2007).
The CDC diagnostic criteria [16] were used, along
with those of the International Pediatric Sepsis Consen-
sus Conference [17], as was recently proposed [18]. An
infection was defined as nosocomial when it appeared
after 48 hours of PICU admission and if there was no
evidence that the infection was present or incubating at
the time of PICU admission.
Diagnosis of BSI included both laboratory confirmed
infections, and clinical sepsis. Clinical sepsis was defined
as such when a physician prescribed treatment for sep-
sis, in a patient with signs and symptoms of sepsis with
no other apparent site of infection, and blood culture
was negative or no blood culture was performed.
Laboratory confirmed infection was diagnosed when: a)
a recognized pathogen was isolated from one or more
blood cultures and this pathogen was not associated to
infection at another site in a patient with signs or symp-
toms of severe infection or; b) a patient had a diagnosis
of sepsis and a common skin contaminant (like coagu-
lase-negative Staphylococcus, CNS) was isolated from
two or more blood cultures drawn on separate occa-
sions, or when it was isolated in a patient with an intra-
vascular line and had treatment for sepsis prescribed by
a physician. BSI was diagnosed in both, children with
and without CVC. Blood samples were obtained from a
separate peripheral venipuncture after skin preparation
with iodine solution, in amounts according to patient’s
age (< 1y: 1 - 2 ml; 1 - 12 y: 1 - 10 ml; > 12 y: 10 ml).
VAP was defined as early when it developed during
the first 4 days under MV, and late VAP when it
developed after the fifth day [19]. Tracheobronchial
samples were collected through deep tracheal aspirates
from endotracheal tubes (ETT) with a closed suction
technique and urine samples were aseptically aspirated
from the sampling port of the urinary catheter (UC).
No invasive technique for sampling of tracheal secre-
tions was used.
UTI was classified as symptomatic UTI, asymptomatic
bacteriuria and other UTIs, as defined by CDC criteria
[16]. To consider urine samples as positive the number
of colony forming units (CFU/ml) had to be greater
than 10
5 CFU/ml.
All samples (blood, tracheal and urine) were obtained
only after an infection was suspected. All samples were
collected in containers with antibiotic remover (BAC-
TEC, Becton Dickinson, Microbiology system, Cockeys-
ville, MD, USA) and processed in the INSN Laboratory.
Some isolated bacteria were sent to the INS to confirm
bacterial susceptibility by disk diffusion method. All
yeasts isolated at the INSN were sent to the INS and
antifungal susceptibility was determined by disk diffu-
sion method.
Other NIs such as upper respiratory, surgical, enteric,
skin or infections at other sites, were not surveyed. All
admitted children were assessed daily (Monday to Satur-
day) by one of the authors (MRB, MCA or JAT) who
ascertained the presence of signs compatible with NI
and use of devices (CVC, ETT or UC) up to 48 hours of
discharge from the PICU.
At the time of the study there were no approved rules
for insertion of CVCs, but for all insertions masks, ster-
ile gowns and gloves were used, cleaning the skin with
clorhexidine 2% plus disinfection with alcohol 70% and
c o v e r i n gt h ep u n c t u r es i t ew i t hs t e r i l eg a u z ea n dt r a n s -
parent dressing. Written rules for prevention of cathe-
ter-associated BSI approved by the Infection Control
Committee were in use since 2003. The connecting
tubes were changed every third day, unless CVCs were
used for TPN or blood transfusions, in those cases it
was changed every day. Any drug administration was
preceded by cleansing of the three-way stopcock with
70% alcohol. The puncture site was cleansed with alco-
hol only if soiling was observed. There were written
guides for ETT and UC care. Aspiration of secretions
was made according to patient’s condition, with aseptic
technique, previously irrigating with sterile normal
saline. All patients with UC in place had a closed drai-
nage system, except infants under 1 month of age.
Manipulation of UC was always with aseptic technique.
The total of patient-days and days of use of devices
(CVC, ETT and UC) were recorded. NIs can be
described by the incidence rate (per 100) using the num-
ber of each assessed infection as numerator and the
number of patients with risk factors as denominator, or
by device-associated incidence rate (DI) (per 1000)
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number of days which patients were exposed to risk fac-
tors. For calculating density of incidence of BSI and UTI
only children with CVC or UC were considered. A ven-
tilator, CVC or UC day was considered as such only if
the device was placed during the morning hours (until
13:00). The ratio of use of devices was estimated divid-
ing number of days of use of a device between days the
patients spent at the ICU.
Crude excess mortality was defined as the difference
between mortality in children with and without NI.
PRISM score was calculated during the first 24 hours of
admission.
We performed descriptive analysis of central ten-
d e n c ya n dv a r i a b i l i t ym e a s u r e m e n t sa sw e l la sr a t ee s t i -
mates. To perform bivariate and multivariate analysis
to determine the risk for NI linear generalized models
with Poisson family and log link adjusted values for
age, sex and PO condition were used. Furthermore, the
Kaplan-Meier analysis for survival was performed for
t h et i m eo ft h eN Ie v e n ta tt h eI C Ua n df o rd e a t ha t
ICU. Categorical variables were evaluated using the chi
square or Fisher’ exact test, as appropriate. Continuous
variables were evaluated using the Mann-Whitney test.
Proportions were compared using the z test, median
test to compare medians and Mann Whitney’sUt e s t
to compare averages. We used the stata 8.0 statistical
program (Single user Stata for Windows perpetual
license. Serial number: 8199049125. Licensed to: Insti-
tuto Nacional de Salud).
Results
Demographic features and use of devices
There were 444 admissions for 414 patients (18 patients
were admitted twice and 6 were admitted 3 times). The
average age was 52.8 months (range: 0.02 - 214; SD
62.9; first quartile: 4.0, third quartile: 103.7) and the
median was 19 months; 189 children (46%) were under
1 year. Demographic features, reason for admission,
comorbidities, patient-days, use of devices, length of stay
and mortality for patients with and without NI are
described in Table 1. The group of children with NI was
younger; however reasons for admission to PICU as well
as comorbidities were similar in both groups. No pre-
term infant was admitted during the study period.
Table 1 Demographic features, comorbidities and device
use in children
Of all admissions, 52% came from the Emergency
Department. Of admitted children, 43% had a CVC, 70%
ETT and 38% UC. The ratios of use of devices were
0.46, 0.74 and 0.25 for CVC, ETT and UC respectively.
PICU mortality for the entire population during the
study period was 23.6%. The Kaplan-Meier analysis
shows that 50% of deaths occurred by the sixth week at
PICU (Figure 1).
Figure 1. Time of death
Features of Nosocomial Infections (Table 2)
Out of 414 admitted patients 81 (19.5%) developed an
N I ,m o s to ft h e mi nc h i l d r e n<1y e a r( 5 6 . 5 %o fN I s )
Table 1 Demographic features, comorbidities and device
use in children
WITH NI
(n = 81)
WITHOUT
NI
(n = 363)
P ALL
(n = 444)
AGE
months, median 7.7 24 0.002 19
GENDER
M/F 50/31 192/171 - 242/202
Medical n (%) 68 (84) 272 (75) 0.053 340 (76.6)
respiratory 21 60 - 81
neurological 86 9 - 7 7
septic 21 49 - 70
others 18 94 - 112
Post operative n (%) 13 (16) 91 (25) 0.053 104 (23.4)
neurosurgery 24 5 - 4 7
others 11 46 - 57
COMORBIDITY
total (%) 45 (56) 163 (45) 0.081 208 (47)
congenital
syndromes
30 79 - 109
chronic conditions 11 52 - 63
neoplasia 22 6 - 2 8
others 26 - 8
PRISM * average 7 ± 6.7 6.47 ± 6.63 0.74
PATIENT DAYS 2689 1914 - 4603
DEVICE USE
CVC days 1180 922 - 2102
ventilator days 2091 1329 - 3420
UC days 620 550 - 1170
DEVICE UTILIZATION
RATIO
CVC 0.44 0.48 - 0.46
ETT 0.78 0.69 - 0.74
UC 0.23 0.28 - 0.25
ICU STAY (days)median 23 6 <
0.001
6.9
MORTALITY
PICU, n (%) 31 (38.3) 74 (20.4) <
0.001
105 (23.6)
Hospital, 28 d (%) 36 (44.4) 119 (32.7) 0.060 155 (34.9)
* data from 97 patients (20 with and 77 without NI).
NI: nosocomial infection; CVC: central venous catheter; ETT: endotracheal tube;
UC: urinary catheter.
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(49 cases), 29 of them with laboratory confirmation and
20 with clinical sepsis; 38/49 BSIs presented in children
with CVC; amongst these 38 catheter-related BSI some
microorganism was isolated in 29, and 9 were clinical
sepsis. VAP was observed in 27 cases (5 early; 22 late
VAP) and symptomatic UTI in 9; 6/9 UTIs presented in
children with UC. DI for BSI, VAP and UTI was 18.1,
7.9 and 5.1 per 1000 days of use of CVC, MV and UC
respectively. Incidence rate for NI in children with CVC,
ETT or UC was 3.0, 2.7 and 2.7 per 100 patient days,
respectively. Median ICU stay before NI diagnosis was
7 days.
Table 2. Features of nosocomial infections
Rates of incidence were: 38/190 (20%) for BSI; 27/313
(8.6%) for VAP and 6/168 (3.6%) for UTI. Rate of inci-
dence of BSI in patients with CVC was greater than in
patients without CVC (20% vs. 4.7%, p < 0.05), whilst
rate of incidence of UTI in patients with UC was not
significantly greater than in patients without UC (3.6%
vs. 1.1%, p = 0.14).
The median length of stay (LOS) in ICU for children
without NI was 6 days (range 2-60), whilst in those with
NI it was 23 days (range 5-268) (p < 0.001). The LOS,
previous to diagnosis of NI, in children with NI was
significantly greater than LOS in children without NI
(12.3 vs. 6 days, p < 0.001). The average additional stay
after diagnosis of NI was 20.8 days, which accounted for
60% of stay for infected patients. Median LOS for indivi-
dual NI was 22.5, 25 and 34 days for BSI, VAP and UTI,
respectively.
PRISM was calculated in only 22% of patients and it
was no different between those patients with NI (7)
compared to those without NI (6.6) (p = 0.74).
Mortality in PICU was greater amongst patients with
NI (38.3%) than in patients without NI (20.4%) (p <
0.001), with a crude excess mortality of 17.8%. Mortality
after 28 days of discharge from PICU was greater in
children with NI, although without statistical signifi-
cance (44.4% vs. 32.7%; p = 0.06). Mortality for BSI,
VAP and UTI was 30.6%, 51.8% and 22.2% respectively.
Mortality in children with CVC and BSI was greater
than in children with CVC but no BSI, with no statisti-
cal significance (42.1% vs. 28.9%, p = 0.135). Mortality
in patients with VAP was greater than in patients with-
out VAP (51.8% vs. 31.1%, p < 0.05). Mortality in
patients with VAP was 59% (late) and 20% (early). Mor-
tality for UTI (22.2%) was not different from that of the
entire population (23.6%).
Distribution of pathogens
BSI (29 isolates)
In 59% of cases of BSI at least one microorganism was
isolated in blood cultures. The most common was Can-
dida (41% of isolations) of which 10 (83%) were non-
albicans (two cases of glabrata, krusei, tropicalis each;
one case of lipolitica, guilliermodi, parapsilosis, sp each)
and 2 (17%) were C albicans. Candida was only isolated
from children with CVC. Enterococcus was not isolated.
Figure 2 shows pathogens isolated in BSI. Out of 4 iso-
lated Pseudomonas,3w e r eaeruginosa and one fluores-
cens; included in “others” were the following: Klebsiella
oxytoca, Acinetobacter sp, Providencia stuartii, Acremo-
nium sp and Kodamaea ohmeris (one each).
Figure 1 Time of death. The Kaplan-Meier curve describes (in
weeks) the time of mortality.
Table 2 Features of nosocomial infections
Infections acquired at ICU Rate
Rate of infection (UCI)/1000 26,3
Ventilator Associated Pneumonia rate/1000 7,9
Catheter Related Blood Stream Infection rate/100 18,1
Catheter Related Urinary Infection rate/100 5,1
Calculated device-associated infection rate/1000 12,5
Figure 2 Pathogens isolated in ICU patients with BSI. Candida
spp was the most common microorganism in bloodstream
infection.
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VAP (31 isolates)
In 97% of VAPs at least one microorganism was isolated
from tracheal aspirate, Pseudomonas (52%) was the most
common isolate. In 6 children, more than 1 microorgan-
ism was isolated. Gram negatives were less common in
early VAP. Eleven multiresistant Pseudomonas were
detected, 7 of them were isolated during the first 3
months of the study. This lead to introduce effective
control measurements for NI. Figure 3 shows pathogens
isolated in VAP. Out of 16 Pseudomonas,1 5w e r eaeru-
ginosa and 1 fluorescens; isolated Gram positive cocci
were Sa u r e u s ,Sc o h n n iyS t r e p t o c o c c u sm i t i s(one
each); one C albicans and one C glabrata were isolated.
Figure 3. Pathogens isolated in ICU patients with VAP
UTI (7 isolates)
In 86% of cases at least one microorganism was isolated.
Candida was isolated in 5/7 cases (4 albicans and 1 sp);
One Klebsiella pneumoniae and one E coli were isolated.
All strains (5) of CNS causing BSI, were resistant to
oxacillin and susceptible to vancomycin. All isolated
fungi strains (except Ck r u s e i )w e r es e n s i b l et of l u c o n a -
zole and voriconazole. Pseudomonas isolated in ETA
had high antibiotic resistance rates: 13/16 for ceftazi-
dime, 14/16 for amikacin and ciprofloxacin and 12/16
for meropenem.
Six strains produced extended-spectrum-beta-lacta-
mase (ESBL): one of 3 isolations of E. coli and 5 of 10
isolations of Klebsiella. Four strains were isolated from
ETA (one E. coli and 3 K. pneumoniae); two others
came from blood cultures (K. oxytoca) and urine culture
(K. pneumoniae). No ESBL producing strain was resis-
tant to meropenem.
The bivariate analysis adjusted by sex, age and post-
operative status found that the use of ETT (RR 22.9; CI
5.6,93.8), CVC (RR 3.6; CI 2.2,5.9) and UC (RR 2.0; CI
1.2,3.1) increased the risk of developing an NI. Using
two devices increased the risk for NI (RR 2.6; CI
1.3,4.9), as well as using three devices (RR 3.6; CI
1.9,7.1). A 45 day stay doubled the risk for NI (RR 1.95;
CI 1.6,2.3). Use of ETT for 15 days increased the risk of
NI by 1.39 (CI 1.29,1.49) whilst the use of CVC and UC
f o r1 0d a y si n c r e a s e dt h er i s ko fN Ib y1 . 7 3( C I1 . 5 2 ,
1.96) and 1.56 (CI 1.36,1.79) respectively.
Results of the multivariate analysis can be seen in
Table 3. It shows the 3 variables adjusted for age, sex
a n dp o s t o p e r a t i v ec o n d i t i o nt h a tr e s u l t e da s s o c i a t e dt o
NI. The presence of ETT, time of use of ETT and time
of use of CVC are associated to the development of NI.
Table 3: Multivariate analysis of children in the PICU
The cumulative incidence of NI is shown in Figure 4.
Figure 4. Cumulative incidence of nosocomial infections
in the Pediatric Intensive Care Unit
Discussion
Surveillance of NIs may help in decreasing the incidence
of infections and reducing costs. In this study, 20% of
patients in a PICU of a developing country developed
an NI, BSI being the most frequent. Unexpectedly, Can-
dida spp was the most common cause of BSI.
There are some limitations of this study, particularly
when it is to be compared with others [1-4,6,13]. First,
we studied only 3 types of NI. Secondly, our study did
not aim to identify all nosocomial pneumonias but
VAPs. Despite that 95% of nosocomial pneumonias are
VAPs [20], this must be borne in mind when comparing
figures. Finally, we did not search for viral agents, and it
is known that virus can cause almost 20% of NIs in chil-
dren [21].
NIs can be defined in different ways, thus assessment
and comparison can be complicated. However, NIs are
better expressed using as denominator the number of
patients or number of days of use of devices. Use of
devices is an indicator of patient’s severity of illness or
of invasive routines in ICU [22] and is strongly asso-
ciated to development of BSI, pneumonia and UTI [3].
As in most pediatric studies [2-4], we found BSI as the
most frequent NI. Only one study in Brazil [13] and
Figure 3 Pathogens isolated in ICU patients with VAP.G r a m
negative predominated in VAP. Only one S aureus was isolated.
Table 3 Multivariate analysis of children in the PICU
RR P > z CI 95%
Uses ETT
No Ref
Yes 14.8 < 0.001 3.6 61.5
Time of use of ETT
Days 1.01 0.024 1.00 1.02
Time of use CVC
Days 1.03 0.005 1.01 1.05
RR: relative risk; CVC: central venous catheter; ETT: endotracheal tube.
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common.
Our ratio for use of CVC, ETT and UC (0.46, 0.74
and 0.25 respectively) was, compared with NNIS reports
(0.46, 0.43 and 0.32) [22], noticeably greater for ETT
and similar regarding the use of CVC and UC. Despite
similar use of CVC we had more BSI (18.1 vs. 7.3 - 8.9
per 1000 days of use of CVC [3,22]); this fact has also
been described for NI in adult ICUs in developing coun-
tries [15]. It is likely that this increase in frequency of
BSI is due to a greater susceptibility of our patients, dif-
ferences in catheter insertion techniques or further care,
or both. The aforementioned study [15] attributed the
greater frequency of NI to less frequency of hand
hygiene, low nurse-to-patient-ratios, and outdated
technology.
T h ed e n s i t yo fi n c i d e n c ef o rV A Pa n dU T Is e e mt o
correspond to greater and similar use of ETT and UC,
respectively. On the other hand, two studies regarding
risk factors found 13.8 BSI/1000 days of use of CVC
[23] and 11.6 VAP/1000 days of use of ETT [9], whilst a
surveillance study for VAP found 8.9 VAP/1000 days of
use of ETT [12]; these figures are closer to ours.
Increased VAP rates could be due to greater rate of
device use [22], as mentioned previously, but also to
other factors. In our study, 30% of patients had a genetic
syndrome, and the use of antibiotics (90%), sedation
(75%), transfusions (70%), H2 blockers (60%), steroids
(50%) and inotropes (40%) was highly prevalent; all
these have been considered as potential risk factors for
VAP [9,12].
The isolation of Candida spp. as the most common
isolate in our children with BSI, in contrast with
studies that show CNS as the principal causing agent
[2-5,23,24], has already been pointed out [4]. There has
been an increase in Candida BSI infections over the last
years, as well as a shift toward non-albicans Candida
[24,25]. Risk factors for candidemia are previous coloni-
zation, long ICU stays, presence of CVC, parenteral
nutrition, MV, illness severity and prolonged use of anti-
biotics [25-27]. It is likely that the most important cause
of our high prevalence of Candida is the extensive use
of broad spectrum antibiotics [26]. Although at INSN
vancomycin, carbapenems and ciprofloxacin must be
approved by an infectologist before its use, third genera-
tion cephalosporins, vancomycin, and amikacin are fre-
quently used at our institution, and more than 90% of
PICU patients received any of these antibiotics or cipro-
floxacin both in the PICU and previous to PICU admis-
sion. Long ICU stay is also described as a risk factor for
candidemia [26], and although not described in the
results section, children with BSI due to Candida had
ICU stay almost twice longer than children with BSI
due to other microorganisms (average, 53 vs. 27 days).
Also not shown, previous surgery in children under
12 months was more frequently seen in children with
BSI due to Candida than in children with BSI due to
other microorganisms (75% vs. 29%). We have no
Figure 4 Cumulative incidence of nosocomial infections in the Pediatric Intensive Care Unit. Graphic shows the cumulative incidence (in
days) of nosocomial infections.
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researched in future investigations. Other possible
causes are previous colonization with Candida,d u et o
the high use of antibiotics, as well as our high use of
intubation and MV [26]. Candidemia is particularly
important, because it is associated with high mortality,
both in adults [28] and children, especially at lower ages
and in those with comorbidities [26]. Due to its increas-
ing numbers, more studies about risk factors for Can-
dida infection are needed.
Gram negatives, mainly Pseudomonas, caused 80% of
VAP in our study. Pa e r u g i n o s ais the most common
organism in children with VAP, followed by other Gram
negatives and S. aureus [1,3,4,9,12,29,30]. There was just
one case of S. aureus in our study, possibly because
many children are admitted to the ICU having been
treated with vancomicin.
The most common organisms in UTI are E. coli [2,3]
or, as in our study, Candida [4,31]. We found 5 Can-
dida, 4 of them were associated to urinary catheters.
We had a high rate of antibiotic resistance. All CNS
causing BSI were resistant to oxacillin and around 80%
of Pseudomonas in children with VAP were resistant to
ceftazidime, amikacin, ciprofloxacin and meropenem.
Resistance pattern is high at INSN: 50% of Sa u r e u sare
resistant to oxacillin, 85% of Klebsiella are resistant to
third generation cephalosporin and 50 - 90% of Pa e r u -
ginosa are resistant to carbapenems, amikacin, ceftazi-
dime and ciprofloxacin (source: Committee on
Nosocomial Infections). We believe that this is due to
the extensive use of antibiotics.
Mortality of NI in the present study was 38%, notably
greater than that reported from PICUs of developed
countries (7.7 - 10%) [1,2], and somewhat greater than
that from a PICU of Brazil (28.3%) [13]. Mortality in
Latin American countries tends to be greater than that
in the USA. A study in 6 PICUs from this region found
greater mortality than expected among lower risk
patients (PRISM < 10), compared to one PICU in USA,
which could be explained on the basis of increased use
of central lines and ETT as well as broad spectrum anti-
biotics [32].
Described mortality for BSI is 14 - 26.5% [5,23,24]; we
found 31%, this could be related to greater severity of
disease, differences in management or both. Notwith-
standing we found greater mortality (46%) for BSI due
to Candida than with other organisms, the limited num-
ber does not allow us comparative analysis.
Nosocomial pneumonia is the main cause of death in
children with NI [30], but it is doubtful if VAP increases
mortality in children on MV. In contrast to other
studies [9,12], our mortality for VAP was significantly
greater than for children without VAP. In a study from
a developing country, the risk adjusted PICU mortality
was significantly greater in VAP versus non-VAP
patients [33]. Mortality for VAP seems also be related to
the causative pathogen and the time of onset [8,19]. For
example, Gram negative bacilli (particularly Pseudomo-
nas) have > 80% mortality [8], and early VAP has smal-
ler mortality than late VAP [19]. Our limited numbers
(5 early and 22 late VAPs) forbid further analysis, but
we found a tendency to greater mortality in late VAP.
We have found no pediatric studies that have researched
on this topic beyond the neonatal area.
A striking feature of our data is that ICU stay previous
to NI diagnosis was greater for this group than for chil-
dren who did not develop an infection. It is known that
NIs increase hospital stay [1,9,12,23], but also a longer
stay per se is a risk factor for NI [34]. That suggests that
patients who developed an NI were already significantly
different from those who did not, which is particularly
important for future studies and when interpreting the
impact of the NI. Since a significant portion of our
patients had co-morbidity, it is possible that its condi-
tion resulted in a longer stay, predisposing them to NI.
By the other hand, although in bivariate analysis ICU
stay was associated to NI development, in multivariate
analysis it did not result significant.
This study has several restrictions, like the lack of
inclusion of data on re-intubation, which could be rele-
vant for VAP; likewise, the sample collecting technique
(tracheal aspiration) is not the one recommended by
most authors. PRISM score was recorded in only 22%
of patients. Neither did we stratify cases according to
severity of disease, which could influence the appear-
ance of NI, mortality and stay. Finally, it must be borne
in mind that the INSN is a national reference center
and admits children from other institutions, thus our
results may differ from other PICUs. Additionally, we
were not able to calculate attributable mortality because
data that could have influenced the results was not
available.
Conclusions
This study highlights the importance of NIs in children
admitted to a PICU in a developing country. Patients in
these units, despite representing a small percentage of
inpatients, contribute with over 20% of NIs [35]. Poten-
tial impact of NI control is such that of 6 recommenda-
tions to improve interventions in health, issued by the
Institute for Health Improvement, 3 are directly related
to actions to decrease NIs [20]. In the ICU at the INSN
one of every 5 children acquires an NI, which was asso-
ciated with increased mortality and length of stay.
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